Welcome to our dedicated page for NICE Ltd. SEC filings (Ticker: NCSYF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
NICE Ltd. filings document the company's foreign-private-issuer reporting through Form 6-K submissions. The records include furnished press releases and exhibits on GAAP financial statements, cloud revenue, AI annual recurring revenue, share repurchases, and financial outlook, with selected financial statements incorporated by reference into Form S-8 registration statements for equity compensation plans.
The filings also record product and customer announcements for NiCE CXone, NiCE Cognigy, and NICE Actimize, including contact-center-as-a-service, AI agents, interaction analytics, fraud detection, financial-crime risk management, and KYC solutions. Governance disclosures cover special general meeting notices, record dates, proxy and electronic voting mechanics, and instructions for American Depositary Share holders.
NICE Ltd. is rescheduling its special general meeting of shareholders from May 28, 2026 to June 2, 2026 at 3:00 p.m. Israel time, at the company’s registered offices. The record date to determine who may receive notice and vote remains April 30, 2026.
Shareholders’ previously submitted proxy cards and voting instructions remain valid unless revoked or changed before the applicable cut-off. The cut-off for electronic voting and proxy cards is May 31, 2026 at 3:00 p.m. Israel time, and for American Depositary Share holders May 29, 2026 at 9:00 a.m. New York time.
BlackRock, Inc. reported beneficial ownership of 3,218,304 shares of NICE LTD common stock, equal to 5.3% of the class as of 03/31/2026. The filing states BlackRock has sole voting power over 2,958,929 shares and sole dispositive power over 3,218,304 shares. The Schedule 13G was signed on 04/27/2026.
NICE Ltd. furnished a Form 6-K highlighting multiple milestones around its AI-driven customer experience and financial crime platforms. The company showcased new “agentic AI” capabilities in its NICE Cognigy offering that turn enterprise interaction data into production-ready AI agents, aiming to move customers from pilots to scaled deployment.
NICE reported industry recognition, including a Best Innovation for Customer Experience award at Enterprise Connect 2026 for its data-to-agent automation, and NICE Actimize being named a Luminary in Celent’s 2026 KYC Solutionscape. The filing also notes NICE’s inclusion as 11th in Fast Company’s 2026 World’s Most Innovative Companies list in the Applied AI category, reflecting growing visibility for its unified, AI-native CX and compliance platforms.
NICE Ltd. Chief Executive Officer Russell Scott Edward reported a tax-withholding disposition of 2,051 Ordinary Shares at $110.26 per share. This was not an open-market sale but shares withheld to satisfy tax obligations. After this transaction, he directly holds 63,938 Ordinary Shares. This holding includes 30,250 restricted stock units and 15,125 performance stock units, each representing a contingent right to receive one Ordinary Share as they vest under their award terms.
NICE Ltd. reported that VP, General Counsel & Corporate Secretary Levy Meir Alon received a grant of stock options. The award covers 5,000 options for Ordinary Shares with an exercise price of $0.3211 per share and an expiration date of April 1, 2032.
The options vest in substantially equal installments on April 1, 2027, April 1, 2028, April 1, 2029, and April 1, 2030. Following this grant, Alon holds a total of 5,000 options directly.
NICE Ltd. reported that VP of Corporate Finance Dayan Udi Yehuda received a grant of 5,000 stock options linked to 5,000 Ordinary Shares. The options have an exercise price of 0.3211 per share and expire on April 1, 2032. According to the disclosure, the stock option will vest in substantially equal installments on April 1, 2027, April 1, 2028, April 1, 2029, and April 1, 2030. This is a compensation-related award, not an open-market purchase or sale, and after the grant he holds 5,000 options directly.
NICE Ltd. director Zehava Simon filed an initial statement of beneficial ownership, outlining existing holdings in options and ordinary shares. The filing lists multiple option grants over ordinary shares with exercise prices ranging from 0.2657 to 232.2005 and expiration dates between 2026 and 2031. Footnotes state that some stock options are already fully vested and exercisable, while others vest over time, including one grant that vests in three substantially equal installments on March 30, 2026, June 30, 2026 and September 30, 2026. The filing also reports direct ownership of 3,439 ordinary shares, giving investors a clear view of the director’s current equity stake rather than any new transaction.
NICE Ltd. director Dvir Yocheved has reported current equity holdings in a Form 3 insider filing. The disclosure lists multiple stock option awards over NICE ordinary shares with exercise prices ranging from 0.2929 to 232.2005 and expiration dates between 2026 and 2031. The filing also shows direct ownership of 395 NICE ordinary shares. Footnotes explain that some options are already fully vested and exercisable, while others will vest in installments through specific dates in 2026.
NICE Ltd. executive Udi Yehuda Dayan, VP of Corporate Finance, filed an initial insider report listing existing stock option holdings in the company’s Ordinary Shares. The filing shows options over 750 Ordinary Shares at an exercise price of 0.3060 expiring on March 14, 2028, and 3,000 Ordinary Shares at an exercise price of 0.3134 expiring on December 23, 2031, among other grants. Footnotes explain that some options are already vested and exercisable, while others will vest in scheduled installments through 2030. No new purchases or sales are reported; this Form 3 simply establishes Dayan’s existing option positions.
NICE Ltd. executive vice president of human resources Neder Shiri reported existing holdings of stock options on the company’s Ordinary Shares. The awards have exercise prices ranging from 0.2706 to 0.3228 and individual grants covering 1,200 to 12,500 underlying shares, with expirations between March 3, 2027 and February 18, 2033.
Footnotes explain that several options are already vested and exercisable, while others vest over future dates in 2027, 2028 and 2029. One performance-based grant is eligible to vest over a three-year performance period ending February 18, 2029, depending on specified stock price thresholds.